Clinical Trial Update: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for RSO-021 in malignant pleural effusion due to advanced/metastatic solid tumors including mesothelioma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Malignant Pleural Mesothelioma
• Mesothelioma

Drugs mentioned

• RSO-021

Snippet

Sponsor: RS Oncology LLC | Conditions: Malignant Pleural Effusion, Malignant Pleural Mesothelioma | Phase 1, Phase 2 | Status: UNKNOWN